latest news on glp 1 drugs GLP-1 Agonists Weight Loss Market Report, 2025-2030 The GLP-1 revolution: What UAB

doi: 10.2174/1573399813666170621123227

Who Are Weight Loss Medications Not a Good Fit For

Exendin-4 (E4), a long-acting GLP-1RA, has demonstrated neuroprotective effects in early experimental DR [49, 50]

Quddos F, Hubshman Z, Tegge A

In addition, GLP-1 can slow gastric emptying, reduce appetite in patients and thus reduce body mass, control blood pressure, regulate blood lipids and protect cardiovascular function, and has a low risk of hypoglycemia

I have been long LLY and NVO because of GLP-1 drugs since early 2022, but as evidence continues to amass in favour of their utility for a large population its worth considering - what other implications does this have